Anuh Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported FY2026 revenue of Rs. 77,166 Lakhs, up 16.6% from Rs. 66,151 Lakhs in FY2025, driven by higher volumes in bulk drugs and chemicals. However, profit after tax declined 13.3% to Rs. 4,105 Lakhs from Rs. 4,735 Lakhs, impacted by rising raw material costs and unfavorable forex movements. EBITDA margin compressed to 8.56% from 10.64% in the prior year. The company declared a dividend of Rs. 1.50 per share (30% payout) subject to shareholder approval. A 1:1 bonus issue was completed in July 2025, doubling the equity share capital to Rs. 5,011 Lakhs. The audit opinion remains unmodified with no qualifications. Nine promoter group shareholders (holding 0.95% stake) have sought reclassification to public category.
Revenue growth of 16.6% shows solid business expansion, but the 13.3% PAT decline and EBITDA margin compression of over 2 percentage points signal cost pressures that may concern investors. The clean audit and dividend declaration provide some support. The promoter reclassification request is minor at under 1% stake.